Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (279)
- COVID-19 (163)
- Safety monitoring and information (104)
- Legislation (96)
- Compliance and enforcement (72)
- Manufacturing (57)
- Vaping hub (55)
- Labelling and packaging (38)
- Import and export (29)
- Scheduling (national classification system) (27)
- Medicinal cannabis hub (25)
- Sunscreens (18)
- Weight loss products (15)
- Shortages and supply disruptions (13)
- Committees and advisory bodies (9)
- Cosmetics (5)
- Unique Device Identification (UDI) hub (4)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
1273 result(s) found, displaying 726 to 750
-
Media releasesOn 27 September 2021 the TGA granted provisional determination to Roche Products Pty Ltd in relation to the COVID-19 treatment tocilizumab (ACTEMRA).
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe TGA has issued two infringement notices totalling $26,640 to Tianda Pharmaceuticals Australia Pty Ltd for alleged unlawful advertising of a listed medicine in relation to COVID-19.
-
Regulatory decision noticesThis labelling exemption is granted under section 1.5.5 of Part 2 of the current Poisons Standard.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Regulatory decision noticesInformation about the Senate inquiry into the ‘Number of women in Australia who have had transvaginal mesh implants and related matters.’
-
News articlesOn 28 March 2018, the Senate Community Affairs References Committee reported on its inquiry into the number of women in Australia who have had transvaginal mesh implants and related matters - external site.
-
-
Media releasesLawyers for the TGA have written to United Australia Party leader, Mr Craig Kelly MP, alleging it has breached copyright and demanding that it stop distributing incomplete extracts of adverse event reports relating to COVID-19 vaccines which the TGA believes could be seriously misleading.
-
Media releasesTGA has placed new restrictions on the prescribing of oral ivermectin
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
-
Media releasesThe TGA has granted provisional approval to Moderna Australia Pty Ltd in relation to the COVID-19 vaccine, Spikevax (elasomeran), for individuals aged 12 years and over.
-
BlogFrom 1 October 2021 you will no longer be able to legally buy nicotine vaping products, such as nicotine e-cigarettes, nicotine pods and liquid nicotine, from overseas websites without first getting a prescription.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Compliance undertakingsEnforceable Undertaking given by Shen Neng Herbal Medicines Group Pty Ltd to the Department of Health
-
-
Media releasesJoint statement from the TGA, Ahpra, Office of the Health Ombudsman and the Health Care Complaints Commission
-
Media releasesThe TGA has granted provisional approval to Pfizer Australia Pty Ltd for its COVID-19 vaccine, COMIRNATY, making it the first COVID-19 vaccine to receive regulatory approval in Australia.
-
Regulatory decision noticesThis labelling exemption is granted under section 1.5.5 of Part 2 of the current Poisons Standard.
-
Regulatory decision noticesThis labelling exemption is granted under section 1.5.5 of Part 2 of the current Poisons Standard.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesConducting domestic inspections during the Coronavirus (COVID-19) pandemic
-
Media releasesIvermectin is a prescription medicine that is not approved in Australia (or in other OECD countries) to prevent or treat COVID-19 disease, and should not be imported for this indication.
-
Media releasesOn 20 August 2021 the TGA granted provisional determination to Roche Products Pty Ltd in relation to the combination therapy casirivimab + imdevimab (RONAPREVE)